Cancer Dormancy

Lessons from a B Cell Lymphoma and Adenocarcinoma of the Prostate

Rosalia Rabinovsky, Jonathan W. Uhr, Ellen S. Vitetta, Eitan Yefenof

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Cancer dormancy delineates a situation in which residual tumor cells persist in a patient with no apparent clinical symptoms. Although the precise mechanisms underlying cancer dormancy have not been explained, experimental models have provided some insights into the factors that might be involved in the induction and maintenance of a tumor dormant state. The authors of the present chapter studied a murine B cell lymphoma that can be made dormant when interacting with antibodies directed against the idiotype on its immunoglobulin Ig receptor. This experimental model of antibody-induced dormancy enabled the isolation and characterization of dormant lymphoma cells. The results indicated that anti-Ig antibodies activate growth-inhibiting signals that induced cycle arrest and apoptosis. This process appeared to be balanced by the growth of the tumor cells such that the tumor did not expand. In contrast, antibodies against HER-2expressed on prostate adenocarcinoma (PAC) cells were not growth inhibitory. However, an immunotoxin (IT) prepared by conjugating HER-2 to the A-chain of ricin (RTA) was internalized by PAC cells, followed by induction of cycle arrest and apoptotic death. Infusion of HER-2-specific IT into PAC-bearing immunodeficient mice did not eradicate the tumor but retained it dormant over an extended period of time. Hence, certain aspects of signaling receptors expressed on cancer can be manipulated by antibodies to induce and maintain a tumor dormant state.

Original languageEnglish (US)
Pages (from-to)189-202
Number of pages14
JournalAdvances in Cancer Research
Volume97
DOIs
StatePublished - 2007

Fingerprint

B-Cell Lymphoma
Prostate
Adenocarcinoma
Neoplasms
Immunotoxins
Antibodies
Theoretical Models
Growth
Ricin
Residual Neoplasm
Immunoglobulins
Anti-Idiotypic Antibodies
Lymphoma
Maintenance
Apoptosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cancer Dormancy : Lessons from a B Cell Lymphoma and Adenocarcinoma of the Prostate. / Rabinovsky, Rosalia; Uhr, Jonathan W.; Vitetta, Ellen S.; Yefenof, Eitan.

In: Advances in Cancer Research, Vol. 97, 2007, p. 189-202.

Research output: Contribution to journalArticle

Rabinovsky, Rosalia ; Uhr, Jonathan W. ; Vitetta, Ellen S. ; Yefenof, Eitan. / Cancer Dormancy : Lessons from a B Cell Lymphoma and Adenocarcinoma of the Prostate. In: Advances in Cancer Research. 2007 ; Vol. 97. pp. 189-202.
@article{e62114b595fd4e2f85bfcad5b1956df5,
title = "Cancer Dormancy: Lessons from a B Cell Lymphoma and Adenocarcinoma of the Prostate",
abstract = "Cancer dormancy delineates a situation in which residual tumor cells persist in a patient with no apparent clinical symptoms. Although the precise mechanisms underlying cancer dormancy have not been explained, experimental models have provided some insights into the factors that might be involved in the induction and maintenance of a tumor dormant state. The authors of the present chapter studied a murine B cell lymphoma that can be made dormant when interacting with antibodies directed against the idiotype on its immunoglobulin Ig receptor. This experimental model of antibody-induced dormancy enabled the isolation and characterization of dormant lymphoma cells. The results indicated that anti-Ig antibodies activate growth-inhibiting signals that induced cycle arrest and apoptosis. This process appeared to be balanced by the growth of the tumor cells such that the tumor did not expand. In contrast, antibodies against HER-2expressed on prostate adenocarcinoma (PAC) cells were not growth inhibitory. However, an immunotoxin (IT) prepared by conjugating HER-2 to the A-chain of ricin (RTA) was internalized by PAC cells, followed by induction of cycle arrest and apoptotic death. Infusion of HER-2-specific IT into PAC-bearing immunodeficient mice did not eradicate the tumor but retained it dormant over an extended period of time. Hence, certain aspects of signaling receptors expressed on cancer can be manipulated by antibodies to induce and maintain a tumor dormant state.",
author = "Rosalia Rabinovsky and Uhr, {Jonathan W.} and Vitetta, {Ellen S.} and Eitan Yefenof",
year = "2007",
doi = "10.1016/S0065-230X(06)97008-0",
language = "English (US)",
volume = "97",
pages = "189--202",
journal = "Advances in Cancer Research",
issn = "0065-230X",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Cancer Dormancy

T2 - Lessons from a B Cell Lymphoma and Adenocarcinoma of the Prostate

AU - Rabinovsky, Rosalia

AU - Uhr, Jonathan W.

AU - Vitetta, Ellen S.

AU - Yefenof, Eitan

PY - 2007

Y1 - 2007

N2 - Cancer dormancy delineates a situation in which residual tumor cells persist in a patient with no apparent clinical symptoms. Although the precise mechanisms underlying cancer dormancy have not been explained, experimental models have provided some insights into the factors that might be involved in the induction and maintenance of a tumor dormant state. The authors of the present chapter studied a murine B cell lymphoma that can be made dormant when interacting with antibodies directed against the idiotype on its immunoglobulin Ig receptor. This experimental model of antibody-induced dormancy enabled the isolation and characterization of dormant lymphoma cells. The results indicated that anti-Ig antibodies activate growth-inhibiting signals that induced cycle arrest and apoptosis. This process appeared to be balanced by the growth of the tumor cells such that the tumor did not expand. In contrast, antibodies against HER-2expressed on prostate adenocarcinoma (PAC) cells were not growth inhibitory. However, an immunotoxin (IT) prepared by conjugating HER-2 to the A-chain of ricin (RTA) was internalized by PAC cells, followed by induction of cycle arrest and apoptotic death. Infusion of HER-2-specific IT into PAC-bearing immunodeficient mice did not eradicate the tumor but retained it dormant over an extended period of time. Hence, certain aspects of signaling receptors expressed on cancer can be manipulated by antibodies to induce and maintain a tumor dormant state.

AB - Cancer dormancy delineates a situation in which residual tumor cells persist in a patient with no apparent clinical symptoms. Although the precise mechanisms underlying cancer dormancy have not been explained, experimental models have provided some insights into the factors that might be involved in the induction and maintenance of a tumor dormant state. The authors of the present chapter studied a murine B cell lymphoma that can be made dormant when interacting with antibodies directed against the idiotype on its immunoglobulin Ig receptor. This experimental model of antibody-induced dormancy enabled the isolation and characterization of dormant lymphoma cells. The results indicated that anti-Ig antibodies activate growth-inhibiting signals that induced cycle arrest and apoptosis. This process appeared to be balanced by the growth of the tumor cells such that the tumor did not expand. In contrast, antibodies against HER-2expressed on prostate adenocarcinoma (PAC) cells were not growth inhibitory. However, an immunotoxin (IT) prepared by conjugating HER-2 to the A-chain of ricin (RTA) was internalized by PAC cells, followed by induction of cycle arrest and apoptotic death. Infusion of HER-2-specific IT into PAC-bearing immunodeficient mice did not eradicate the tumor but retained it dormant over an extended period of time. Hence, certain aspects of signaling receptors expressed on cancer can be manipulated by antibodies to induce and maintain a tumor dormant state.

UR - http://www.scopus.com/inward/record.url?scp=34047111239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047111239&partnerID=8YFLogxK

U2 - 10.1016/S0065-230X(06)97008-0

DO - 10.1016/S0065-230X(06)97008-0

M3 - Article

VL - 97

SP - 189

EP - 202

JO - Advances in Cancer Research

JF - Advances in Cancer Research

SN - 0065-230X

ER -